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Delineating the mechanism(s) of BDNF/TrkB mediated proliferation in Neuroblastoma

Timothy Christopher Graham, B.S.
Supervisory Professor: Patrick Zweidler-McKay, MD/PhD

Neuroblastoma is the most common extra-cranial solid tumor in children, arising from
neural crest precursor cells. The neurotrophin receptors (TrkA/B/C) have been implicated as
important prognostic markers, linking the biology of the tumor to patient outcome. High
expression of TrkA and TrkC receptors have been linked to favorable biological features and
high patient survival, while TrkB is expressed in unfavorable, aggressive tumors. Several
studies suggest that high levels and activation of TrkB by its ligand brain-derived
neurotrophic factor (BDNF) stimulates tumor cell survival, proliferation, and
chemoresistance. However, little is known about the molecular mechanisms that regulate
proliferation. The TrkB signaling pathway in neuroblastoma cells has been difficult to
evaluate due to the loss of TrkB expression when the cells are used in vitro. Here we
determined the role of proximal signaling pathways downstream of TrkB on neuroblastoma
proliferation. By analyzing a panel of neuroblastoma cell lines, we found that the SMSKCN cells express detectable levels of protein and mRNA levels of TrkB as analyzed by
western, RT-PCR, and surface expression by flow cytometry. By the addition of exogenous
human recombinant BDNF, we showed that activation of TrkB is important in the
proliferation of the cells and can be repressed by inhibiting TrkB kinase function. By BDNF
stimulation and use of specific kinase inhibitors, the common pathways involving PLC ,
PI3K/AKT, and MAPK were initially investigated in addition to PI3K/MTOR and FYN
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pathways. We demonstrate for the first time that Fyn plays a critical role in TrkB mediated
proliferation in neuroblastoma. Constitutively active and over-expressed Fyn reduced
neuroblastoma proliferation, as measured by PCNA expression. Knockdown of Fyn by
shRNA was shown to cooperate with activated TrkB for an enhanced proliferative response.
Although TrkB activation has been implicated in the proliferation of neuroblastoma cells,
little is known about its effects on cell cycle regulation. Protein levels of pRB, CDK2,
CDK4, CDC25A, cyclin D1, and cyclin E were analyzed following BDNF stimulation. We
found that BDNF mediated activation of TrkB induces multiple common proximal signaling
pathways including the anti-proliferative Fyn pathway and drives cell cycle machinery to
enhance the proliferation of neuroblastoma cells.
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Chapter 1
Introduction
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Neuroblastoma
Neuroblastoma is the most prevalent extra-cranial solid tumor in childhood,
accounting for 15% of all pediatric oncology deaths (1, 2). It arises from the pluripotent
sympaticoadrenal precursor cells in the neural crest, which are the primordial cells of the
sympathetic nervous system. Tumorigenesis starts by the failure of stem cells to
differentiate properly followed by uncontrolled proliferation (3). This is evidenced by
previous research showing that within many types of solid tumors exists a population of
cells responsible for the initial growth of the tumor called tumor initiating cells. These cells
in neuroblastoma exhibit stem cell properties to sustain tumor growth by the ability for self
renewal, however also possess the ability to differentiate into normal neurons or regenerate
phenotype copies that are characteristic of the primary neuroblastoma tumor (4, 5). The
disease predominantly arises in children younger than 4 years old with a median age of 22
months. Neuroblastoma has an incidence rate of about 1 out of 7,000 live births favoring
males to females 1.2:1. An autosomal dominant pattern of inheritance also has been found,
however it is thought to only affect approximately 1-2% of the patient population. The more
common occurrence is the sporadic form, which is associated with a wide variety of factors
such as gain of alleles and oncogene activation (6). The majority of neuroblastoma tumors
are found in the abdominal area with over 50% of cases originating in the adrenal medulla.
Additional sites frequently include brain/neck, chest, and pelvis. The clinical presentation of
the disease is very broad, depending on primary tumor site, the presence of metastatic
disease, and the occurrence of para-neoplastic syndromes (7, 8).
Since the clinical manifestation of the disease is highly variable between individual
patients, the International Neuroblastoma Risk Group (INRG) has developed a staging
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system based on tumor burden and spread. The idea of risk stratification is to ensure proper
decisions to manage the disease by determining which tumors require an aggressive
multimodal therapy versus those that can be managed more conservatively (9). Patients with
stage 1, 2, or 4S or the disease presenting in the first year of life have a good prognosis.
This is typically associated with a locoregional tumor in an otherwise healthy child. In
contrast, a patient presenting with stage 3 or 4 or is past the age of one has a poor prognosis.
Children presenting with stage 4 metatstatic disease and are also over the age of 1 have an
overall survival rate of 10-20%. The child can have an identical presentation to the
locoregional disease, but has a much higher tumor burden along with metastatic lesions (8).
Neuroblastoma is an enigmatic disease due to its diverse clinical and biological
behavior. In some patients less than 12 months of age, even metastatic disease has been
shown to spontaneously regress on its own or following limited treatment, noted as stage 4S.
Interestingly, neuroblastoma is the only disease that has ever been shown to demonstrate
spontaneous regression from an undifferentiated phenotype to a completely benign one. A
potential mechanism to explain the phenomenon is through the regulation of NGF (nerve
growth factor) and the activation of its neurotrophin receptor, TrkA, suggesting an important
role growth factors may play in neuroblastoma biology (10). However, for half of the
patients with stage 4S, particularly those over 12 months of age, the progression of the
disease will continue despite intensive therapy (6, 11). Due to the heterogeneous nature of
the disease, a better understanding of its genetic, biological, and morphological behavior as
well as identifying inherent tumor markers would improve patient survival rate. Further
knowledge of prognostic markers would help stratify patients into regimens that can be
better tailored to their needs on a case by case basis.
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Many prognostic tumor markers that have been identified are associated with the
regulation of proliferation, differentiation, and apoptosis of the cells. MYCN, an oncogenic
transcription factor, is among several important molecular markers that are used to predict
the outcome of the disease. Amplification of MYCN has been shown to be associated with
advanced stages of the disease with rapid tumor progression, seen in about 25% of patients
with neuroblastoma. Even patients with low stages of the disease with localized tumors
have a worse prognosis when MYCN is amplified (12, 13). Other markers that are
important for dictating the severity of the disease include deletion or loss of heterozygosity
of chromosome 1p, gain of chromosome 17q, and notably the expression of the Trk
receptors.
Trk receptors
Trk receptors have been identified as important prognostic factors that influence the
clinical behavior of neuroblastoma (14). Favorable, lower stage neuroblastomas express
high levels of TrkA and C along with their corresponding ligands NGF and NT-3
respectively, which highly correlate with favorable outcomes and overall patient survival by
promoting tumor cell differentiation (15, 16). However, expression of full length TrkB and
elevated levels of its ligand, BDNF, are mainly found in unfavorable, aggressive
neuroblastomas with amplification of the MYCN (17). Additionally, full length TrkB over
expression has been shown to protect neuroblastoma cells from chemotherapy-induced
apoptosis in cell culture systems (18, 19). It has also been shown to promote cell
dissemination and invasive potential, which contributes to the metastatic phenotype
commonly seen (20).
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The field of Trk receptors originally started by the discovery of neurotrophins in the
1940s by Cohen and Levi-Montalcini. However, it was many decades later when their
respective receptors were identified (21). The first member of the Trk family of receptor
tyrosine kinases was initially discovered from a colon carcinoma-derived oncogene. When
the oncogene was isolated and cloned, it was found to consist of the first seven of eight
exons of tropomyosin fused to the transmembrane and cytoplasmic domains of a novel
tyrosine kinase (22). Consequently, this single pass, cell surface transmembrane molecule
was named tropomyosin-related kinase (Trk) and is now commonly referred to as TrkA or
neurotrophin tyrosine receptor kinase 1 (NTRK1). Based off of their high sequence
homology to TrkA, TrkB/NTRK2 and TrkC/NTRK3 genes were identified as well (23, 24).
However, the functional relevance of Trk receptors first came to light whenever they were
identified as a gene capable of transforming immortalized fibroblasts. Once Trk receptors
were linked with their neurotophin counterparts and implicated as being important for the
development of the nervous system, research on them intensified among neurobiologists
(25).
Neurotrophins
Neurotrophins were originally identified as promoters of neuronal survival, but have
since been appreciated to regulate many aspects of neuronal development such as survival
and differentiation. The first neurotrophin, nerve growth factor (NGF), was found while
searching for the reason how motor and sensory neurons survive after ablation and
transplantation studies of target tissues (26). This profound discovery had validated the
theory of neurotrophic factor action, which suggested that targets of neuronal innervation
secrete limiting amounts of survival factors, balancing the size of a target tissue with the

-5-

number of innervating neurons. NGF has since been shown to be internalized by receptordependent processes and transported along axons in membranous vesicles to the cell soma
by cytoskeletal and energy dependent processes (27). Local signaling is shown to regulate
growth cone motility as well as in the soma control cell survival and gene expression. The
neurotrophin is then recycled by a process controlled by lysosomes called ligand turnover.
Even though an abundance of NGF-regulated phenotypes were characterized, a specific
correlating receptor was never found. However in 1991, nerve growth factor was found to
bind to and activate the tyrosine kinase activity of TrkA (28, 29). Subsequently TrkB has
been shown to be activated by BDNF and NT-4/5 and TrkC by NT-3. However some
promiscuity exists in that NT-3 can also bind to both TrkA and TrkB in some cell types, but
less efficiently (30, 31) (Fig.1).

NGF

TrkA

BDNF

TrkB

NT-3

NT-4

TrkC

Fig 1. Representation of Trk receptors with their corresponding ligands.
Differential splicing of exons encoding portions of the Trk intracellular domains can
lead to truncated isoforms of the receptor. Truncated isoforms of TrkB and C have been
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shown to have comparatively short cytoplasmic motifs without a tyrosine kinase motif.
Expression of these isoforms inhibits productive dimerization of kinase-containing Trk
receptors, thereby preventing responses to neurotropins (32).
The major ligand-binding domain for the three Trk receptors has been localized to
the Ig-C2-like domain, proximal to the membrane, which also works in the prevention of
spontaneous dimerization. In addition by point mutation analyses against the Trk receptors,
the domain closest to the transmembrane region was found to play a more prominent role in
activation (33-35). The N termini of neurotrophins have been shown to be important in
controlling binding specificity. Once attached to the Ig-C2 domain of the Trk receptor, the
structure of this region is reorganized, permitting neurotrophins such as NT-3 the ability to
activate more than one type of Trk receptor (36).

TrkB cell signaling in neuroblastoma
Much like other receptor tyrosine kinases, Trk receptors homo-dimerize in response
to ligand binding. The dimeric receptors then phosphorylate one another in trans, leading to
the auto-phosphorylation of three tyrosine residues on the receptor (Y670, Y674, and Y675) to
potentiate an activation loop of the kinase domain. In addition, the active receptor
phosphorylates two main tyrosine residues at Y484 and Y785, which serve as docking sites for
SHC and PTB domain adapter proteins as well as PLC respectively (37, 38). Subsequently,
the recruitment of these adapter proteins leads to the activation of multiple growth factorregulated signaling pathways, which include phosphoinositide-3 kinase (PI3K)/ AKT
pathway (39), release of calcium ions by phospholipase C- (PLC- ) (40), and RAS/
mitogen activated protein kinase (MAPK) (41). In neuroblastoma cells, these pathways
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have important roles that regulate cell proliferation, differentiation, and survival.
Specifically it has been shown that the activation of PI3K/AKT and PLC- pathways have
been shown to mainly enhance cell survival, whereas activating the RAS/MAPK pathways
promotes cell differentiation in neuroblastoma (42).
Recent data by the Thiele lab suggests that TrkB over expression plays a role in the
survival and increased resistance to chemotherapy. The PI3K/AKT axis was identified as
the mediator for BDNF protection in neuroblastoma from chemotherapy induced apoptosis
(19). This survival mechanism has been shown to be initiated by the phosphorylation of
BCL-2-associated death promoter (BAD), a pro-apoptotic member of the BCL-2 gene
family. When BAD is dephosphorylated, it forms a heterodimer with BCL-2 and BCL-XL,
inactivating them and allowing the proteins Bax or Bak to trigger apoptosis. However, when
BAD is phosphorylated, this causes the formation of the BAD-(14-3-3) protein homodimer,
leaving BCL-2 free to inhibit Bax-triggered apoptosis. Additionally activated AKT has also
been shown to signal to and phosphorylate the Forkhead transcription factor (FKRL1), thus
preventing its ability to translocate to the nucleus, and thereby decreasing the transcription
of the pro-apoptotic members Bim and FASL (43). Since AKT is the head of many critical
signaling pathways for cell survival and chemo-resistance, targeting and inhibiting its
activity along with courses of chemotherapy could help treat the disease more effectively.
However, the Serine/Threonine kinase domain of AKT is very similar to the domains of
other proteins, so it has been difficult to develop AKT-specific inhibitors. Similar strategies
are being developed to attack other therapeutically relevant targets along the PI3K/AKT
axis, however very few have shown any promise. This has led researchers to start looking in
other directions for AKT independent mechanisms that may also regulate cell survival and
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growth of neuroblastoma cells. One of those pathways is regulated by a member of the Src
family kinase, Fyn, which has been shown to be important in the development of neuronal
cells (44).
Src family kinases
Src family kinases (SFKs) are nonreceptor tyrosine kinases that phosphorylate
tyrosine residues of various cytosolic, nuclear, and membrane proteins. Srcs were
discovered in the early 1900s, originally described as the oncogene responsible for the tumor
progression of sarcomas in chickens, eventually known as the Rous Sarcoma Virus. Later
they were discovered to be associated with malignant transformations, opening the field of
oncogenesis (45). Since their discovery, an entire family of members has been discovered
that regulate a wide variety of phenotypes ranging from development of neurons (46) to the
oncogenesis of prostate cancer (47). Three distinct members of the Src family of kinases
have been shown to be broadly expressed in the adult CNS: Src, Fyn, and Yes (48). Much
like Src, the over expression of Fyn has been shown to drive the morphologic transformation
in normal cells, as seen in NIH 3T3 fibroblast cells displaying a cancer like phenotype along
with increase anchorage independent growth (49). However, both Src and Fyn have also
been implicated in neuronal differentiation. They were shown to be initially expressed in
neuroectodermal cells during neural fold formation in chickens, which then enrich the
growth cone portion of neural processes upon neuronal differentiation. Their expressions
regulate cell adhesion molecules such as neural cell adhesion molecule (N-CAM), important
for axonal outgrowth and guidance (50, 51).
Fyn plays a critical role in neuroblastoma differentiation
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In addition to the developmental role Fyn plays in neurons, the Eilers group
published an article in Cancer Cell in 2002 showing that over expression of Fyn in
neuroblastoma led to a differentiated phenotype and correlated with low risk tumors (44).
Their results showed that the expression of Fyn protein is correlated with tumor stage in a
panel of patient samples; high expression of Fyn with lower tumor stage and low expression
of Fyn with higher tumor stages. In addition to looking at Fyn expression levels, they
performed a kinase activity assay, which suggested that high Fyn kinase activity was
consistently observed in stage 1 tumors biopsies and that stage 4 tumors mainly expressed
low kinase activity. They showed that high expression of Fyn is a good prognostic marker
for long term survival of neuroblastoma patients and that this trend is independent of MYCN
expression (44).
Overall, their results suggest that Fyn could play an important role in neuroblastoma
differentiation, however the pathways responsible for the activation and signaling of Fyn are
still unknown. Several publications have shown the interaction between Fyn and TrkB. The
Chao research lab found a novel role for Fyn in mediating Trk activation by adenosine in
hippocampal neurons. They show that G-protein coupled receptor (GPCR) activates Fyn by
adenosine, which then co-localizes and activates Trk receptors by phosphorylation (52). In
addition, the interaction between Fyn and TrkB was shown to occur through their SH2
domains in cultured neurons (53). Furthermore, Fyn has also been shown to determine the
localization of TrkB receptors in lipid rafts in neurons (54). These findings help put
together a picture of a potential pathway that characterizes the activity of Fyn through TrkB,
however this interaction has still never been described in neuroblastoma or even in regards
to proliferation or differentiation.
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TrkB plays a critical role in anoikis
To complement the characterization of TrkB mediated proliferation of adherent
neuroblastoma cultures, we also evaluated its role in a suspension environment. A major
contributor to the severity of the disease is the ability for cells to disseminate from the
primary tumor and metastasize to another part of the body. For normal cells, encountering
foreign environments would trigger a process called anoikis, which induces apoptosis of the
cells due to a lack of signaling from the extracellular matrix and unfamiliar cell adhesion
signals. However many types of tumors such as neuroblastoma are anoikis resistant. The
Peeper lab recently used a functional genomic screen to identify TrkB as an onco-protein
responsible for the promotion of metastasis. In vitro, they discovered that over expression
of TrkB caused nonmalignant epithelial cells to become anoikis resistant. Similarly in nude
mice, the TrkB expressing cells also produced highly invasive and metastatic tumors with
short latencies (55). Despite all of their work, the mechanism behind TrkB regulated anoikis
resistance still remains unknown. Furthermore, they show that TrkB plays an important role
in anoikis resistance, but only by an over expressed system in epithelial cells. A model
system that naturally expresses an abundant expression level of TrkB such as neuroblastoma
would enhance the physiological relevance of their finding.
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Significance
Although the treatment effectiveness of neuroblastoma has progressed through the
years, high risk patients are still treated with intensive multimodal therapies that produce
similar, suboptimal cure rates similarly seen in the past. The discovery of Trk receptors has
been an important advancement in the ability to study specific signaling pathways based on
the phenotypes of the neuroblastoma. Although the analysis of the Trk structure as well as
identifying down-stream signaling targets has come a long way, the field is still incomplete.
Further research is needed in order to fully understand the Trk concept from a mechanistic
standpoint.
Hypothesis
Considering the following:
-

TrkB receptors have been identified as an important prognostic maker in
neuroblastoma that dictate poor prognosis of the disease

-

TrkB has been previously shown to regulate proliferation, cell survival, and chemoresistance

-

The mechanism behind TrkB mediated proliferation is still unknown

-

Fyn expression is important for the differentiation of neuroblastoma cells

The research presented in this dissertation was guided by the hypothesis that BDNFmediated activation of TrkB utilizes common proximal signaling pathways to drive cell
cycle machinery to enhance the proliferation of neuroblastoma cells.
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Chapter 2
TrkB characterization in neuroblastoma
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RATIONALE
In previous Trk research, a common problem is the sensitivity of reagents to detect
the TrkB receptor. The TrkB signaling pathway in neuroblastoma cells has been especially
difficult to evaluate as a suitable cell line to measure TrkB signaling has not been available
due to the loss of TrkB expression when the cells are used in vitro. Several labs have turned
to using an exogenous over-expressed TrkB model to research specific phenotypes, however
this method may produce misleading results. The super physiological expression of TrkB
receptors could induce a phenotype that isn’t normally seen with a normal expression level.
In addition, if a pathway of interest was shown to be highly activated in the over expressed
system, it would be difficult to determine whether the results were real or were actually due
to the over abundance of TrkB receptors regulating something that wouldn’t normally be
activated. Furthermore, the relevance of the finding would be called into question if
eventually moved into an in vivo setting because that level of TrkB expression would never
be expressed normally. To avoid the confusion associated with an over expressed system,
we decided to direct our attention to find a suitable cell line that would express a detectable
level of TrkB.
From a panel of 8 neuroblastoma cell lines, SMS-KCN, SMS-KCNR, SK-N-SH,
CHP-134, SHEP, LA-155N, NGP, and SY5Y, we conducted a Taqman Quantitative
Reverse Transcriptase - Polymerase Chain Reaction (qRT-PCR) to evaluate the expression
of TrkB mRNA relative to a GAPDH control (Fig.2a). Although 7 of the 8 cell lines
expressed detectable levels of TrkB mRNA transcript, the SMS-KCN cell line had the most
abundant TrkB expression, 16 fold over the next highest which was SMS-KCNR.
Interestingly, both of these cell lines were derived from the same patient: SMS-KCN derived
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from the primary tumor at diagnosis and SMS-KCNR from a bone marrow biopsy at relapse.
This finding suggests that endogenous over-expression of TrkB plays a major role in the
primary tumor, however still may have an important role in metastasis.

a.
relative expression to GAPDH

70000
60000
TrkB
50000
40000
30000
20000
10000

b.

SMS-KCN SK-N-SH SY5Y

15
5N
LA

13
4
C

H

P-

EP
SH

5Y

-S
-N
SK

SY

H

P
G
N

N
KC
S-

SM

SM

S-

KC

R

N

0

SK-N-AS

Total TrkB
-actin
Fig 2. TrkB expression in a panel of neuroblastoma cell lines. a) Taqman qRT-PCR and b)
Western blot show that SMS-KCN cells have a higher expression level total full length TrkB
compared other neuroblastoma cells lines

However, high levels of mRNA expression may not correlate with high protein levels, so
next we wanted to determine if the mRNA expression of TrkB translated to a detectable
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amount of protein by western blotting. Whole cell lysate was isolated from a panel of cell
lines and probed with total TrkB antibody, which detects all TrkB isoforms, and Beta Actin
as a loading control. Consistent with our RT-PCR results, we found that the protein
expression of SMS-KCN had an easily detectable TrkB protein expression (Fig.2b).
SMS-KCN is an MYCN-amplified neuroblastoma cell line that expresses readily
detectable endogenous levels of both TrkB and BDNF, making this cell line useful for
analyzing the TrkB mechanism from a physiological setting. SMS-KCN cells exhibit an
autocrine BDNF loop that maintains a high level of basal TrkB activation, shown to be
important in stimulating cell survival and neurite extension and its inhibition decreases cell
proliferation (56). Furthermore, Brodeur in 1994 showed that this cell line also expresses
TrkA, but not the low affinity neurotrophin receptor, p75NTR, or its ligand NGF. However,
when the cells were induced with exogenous NGF, TrkA signaling was shown to be
defective due to a lack of kinase function (17). In our experiments, the expression of TrkC
and p75NTR mRNA by RT-PCR was found to be significantly lower than TrkB (~5,300
fold and ~2,000 fold less respectively) suggesting a lack of dependence on those receptors
compared to TrkB (Fig.3). These reports taken together suggest that when exogenous
BDNF is added to the system, the only main Trk signaling pathway activated would be
TrkB.
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Fig. 3. mRNA levels of TrkA, B, C and p75NTR in SMS-KCN cells by Taqman qRT-PCR.

Although SMS-KCN cells express an abundant level of TrkB mRNA and protein
shown by RT-PCR and western blot respectively, the results don’t indicate the location in
the cells. If the expression of cell surface receptors were low, stimulating the cells by
exogenous BDNF wouldn’t provide an adequate signal over basal levels in order to elucidate
downstream signaling targets. However, if a there is a high expression of cell surface
receptors, then this would further suggest that the SMS-KCN cell line would be a good
model system to characterize the TrkB mechanism.
By flow cytometry, we examined the cell surface expression level of TrkB receptors
using a primary antibody for total extracellcular TrkB with a phycoerythrin (PE) conjugated
secondary antibody to detect as a fluorescent tag. SY5Y was used as a negative control cell
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line because TrkB was not detectable by western blotting and didn’t have significant levels
of TrkB mRNA. To quantify, the mean fluorescence intensity was taken from each
measurable group and normalized relative to an unstained control. SMS-KCN cells showed
a ~12 fold higher cell surface TrkB expression when compared to the SY5Y control cell
line. (Fig.4 a,b). This result is consistent with our RT-PCR and western data, showing a
higher TrkB mRNA and protein expression in SMS-KCN cells compared to SY5Y cells.
This finding suggests that SMS-KCN cells do have a high TrkB surface expression that
would be suitable to use as a model to stimulate using exogenous BDNF. However, SMSKCN cells have been previously shown to have an autocrine loop that activates TrkB
receptors at basal level (17). Although the BDNF autocrine loop might result in a high
baseline of activation for TrkB, we believed we could still stimulate a measurable difference
in proliferation by the addition of exogenous BDNF. Next we wanted to analyze whether
these cells could respond to exogenous BDNF to produce a phenotypic response over the
basal activation level of TrkB.
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Fig 4. Surface expression of TrkB by flow cytometry a and b) SMS-KCN cells express 12
fold more cell surface TrkB receptors than SY5Y cells

In a panel of neuroblastoma cell lines (CHP-134, IMR-32, KCNR, SHEP, SK-RG,
SY5Y, and SMS-KCN), we wanted to see whether we could produce a BDNF dose response
using an Alamar blue proliferation assay. The cells were plated in a 96-well plate and
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treated with a range of BDNF concentrations (0 – 100ng/mL) in triplicate for 72 hours. The
Alamar blue dye is a cell viability indicator that uses the reducing power of viable cells to
convert the active ingredient, resazurin, to the fluorescent molecule, resorufin. Only live
cells will continuously produce resorufin, thus providing a quantitative measure of viability
and surrogate for proliferation. Compared to other in vitro proliferative assays that use MTT
indicators, the presence of Alamar blue doesn’t interfere with the reactions of the electron
transport chain, allowing the cells to remain healthy and intact (57). The panel of 7
neuroblastoma cell lines produced a dose-dependent effect with as low as 10ng/mL of
BDNF, for a mean proliferative increase of 43% (Fig.5). This result suggests that all of the
neuroblastoma cell lines exhibit a functional expression level of TrkB to elicit a response.
However, the SMS-KCN cell line, with the most abundant expression of TrkB, was the most
responsive, providing an 80% proliferation increase at only 6.3ng/mL of BDNF. None of
the other cell lines produced such a dramatic effect, even at 100ng/mL of BDNF. The most
reasonable explanation for the BDNF sensitivity is because of the difference in TrkB
expression levels. The difference between adding 100ng/mL of BDNF compared to a lower
concentration is shown to be minimal due to TrkB receptors being the limiting factor. In
addition, another possible explanation is that the BDNF sensitivity of SMS-KCN cells is
controlled by the rate of TrkB recycling. Since SMS-KCN cells are consistently activated
by its autocrine BDNF loop, the rate at which receptors are recycled could be much faster
than a cell line that is not used to constitutive TrkB activation. This in turn would provide
continuous BDNF mediated proliferation in SMS-KCN cells over the 72 hour period.
Regardless, these results corroborate with the TrkB protein and mRNA data found
previously, but it also suggests that those TrkB receptors are functional.
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Fig 5. BDNF induction stimulates the proliferation of a panel of neuroblastoma cell lines
shown by an Alamar blue proliferation assay

Analyzing the data more closely, we saw that SMS-KCN cells were extremely responsive to
BDNF; as low as 0.1ng/mL of BDNF producing a 29% increase in proliferation (Fig.6).
This is important to note because the use super physiological doses of 50-100ng/mL of
BDNF to elicit a phenotypic response could lead to irrelevant, non-physiological results.
Finding that these SMS-KCN cells can react at 0.1ng/mL of BDNF suggests that this is a
specific TrkB event.
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Fig 6. As little as 0.1ng/mL of BDNF can stimulate proliferation of SMS-KCN cells shown
by an Alamar Blue proliferation assay

After showing that TrkB plays a critical role in the proliferation of SMS-KCN cells, we next
wanted to analyze how important these receptors were to the cells by inhibiting their kinase
activity. The Trk inhibitor, AZ23, has been noted to be selective for Trk kinases, compared
to other Trk kinase inhibitors such as K252a and CEP-701 that have been shown to act
against multiple targets (58). AZ23 is a potent, small molecule inhibitor of the Trk kinase
that works by ATP competition. In a panel of cell lines, SMS-KCN, SMS-KCNR, SK-NSH, SK-N-AS, CHP-134, and LA-155N, cells were treated with a range of AZ23
concentrations and incubated for 72 hours in an Alamar blue proliferation assay. We found
that proliferation was prevented in an AZ23 dose-dependent manner in all
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Fig 7. TrkB inhibition leads to decreased proliferation in a panel of neuroblastoma cell lines,
shown by a 72 hour time course proliferation assay treated with/without the Trk kinase
inhibitor, AZ23.

cell lines with IC50s as high as 7 M. At micro-molar concentrations of the inhibitor, other
Trk targets are most likely being affected as well, suggesting that TrkB alone may not be
critical in the proliferation of some of these cell lines. However, the SMS-KCN cell line
was shown to be sensitive to the inhibitor with an IC50 at 0.8 M (Fig.7). This result
suggest the importance of TrkB to survival and proliferation in a number of neuroblastoma
cell lines, but particularly to the SMS-KCN cell line.
To show that AZ23 prevents the activation of TrkB, we measured the
phosphorylation status at Tyr817 using varying concentrations of BDNF by western blotting
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(Fig. 8a). The intracellular phosphorylation sites for TrkB include Tyr516, Tyr702, Tyr706,
Tyr707, Tyr817, however it was previously suggested that Tyr817 and Tyr516 were the main
residues important for transmitting signals that induce pathway stimulation in SMS-KCN
cells (59). First we show that as little as 25nM of AZ23 was enough to inhibit BDNFinduced phosphorylation of TrkB in SMS-KCN cells, suggesting the high potency the
inhibitor has for TrkB. Second, as little as 5ng/mL of BDNF was sufficient to activate TrkB
beyond basal level. This result confirms our previous proliferation assay describing the
sensitivity of SMS-KCN cells to BDNF. Third, the blot also shows that a super
physiological dose at 100ng/mL of BDNF doesn’t produce any additional level of activation
compared to the 25 and 5ng/mL doses.
Our results also show that AZ23 could prevent BDNF mediated proliferation, as
analyzed by an Alamar blue proliferation assay (Fig. 8b). A range of AZ23 concentrations
(0.1 – 10 M) were shown to block the proliferative response of a range of BDNF (0.1 –
10ng/mL) in a dose dependent manner. Although I was able to show that 25nM of AZ23
was sufficient to inhibit BDNF stimulated TrkB activation by western blotting, the results of
the Alamar blue proliferation assay dictated the need for 1 M of AZ23 to block induced
proliferation. This finding suggests that even though TrkB may play a critical role in
proliferation, other pathways need to be stimulated in conjunction to produce the phenotype.
It is possible that the expression of the low affinity BDNF receptor, p75NTR, may play a
role in promoting BDNF activation of TrkB as suggested in other studies (60, 61), which
would warrant the need for a higher concentration of AZ23 for competitive inhibition. As a
way to further characterize the BDNF mediated proliferation as described, we analyzed how
the cell cycle was affected.
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To further test whether the inhibition of TrkB has an anti-proliferative effect in
neuroblastoma, we analyzed the cell cycle of the IMR-32 cell line. SMS-KCN cells proved
to be difficult to work with by flow cytometry due to its nature to aggregate easily. Since
IMR-32 cells responded to BDNF efficiently in my previous Alamar blue proliferation
assay, we used them to model cell cycle expression during TrkB inhibition. However, since
this cell line had a much lower expression of TrkB as seen by protein and mRNA levels, a
higher range of doses of AZ23 was needed in order to see an effect compared to SMS-KCN
cells. Triton permeabilization was used to incorporate the intercalating agent, Propidium
Iodide (TPI) into the cells to stain DNA. From there, the status of DNA can then be
analyzed to see what phase of the cell cycle the cells are in based on the total amount of
DNA, which is represented as FL3-area in the graph (Fig. 9). The lowest FL3-area from ~075 units of fluorescence correlates with DNA in the sub G0 phase, ~75-125 units is the
G0/G1 phase, ~125-150 units is S phase, and ~150-200 units is the G2/M phase. The results
show an AZ23 dose dependent decease of fluorescent intensity levels at the S and G2/M
phases (cycling phases for cell division) suggesting a G2/M arrest of cell cycle (Table 1).
Since the G0/G1 phase did not exhibit a dose dependent decrease, this suggests an increase
in cell death, shown in the sub G0 phase (Fig. 10). Studies by the Theile lab (62) and
confirmed by our findings indicate the important role that TrkB plays in survival and
proliferation in neuroblastoma cells. In addition, Thiele shows that TrkB signaling
stimulates neuroblastoma disaggregation and invasion, which taken together with cell
survival are characteristics of metastatic cells. We decided to investigate the role TrkB may
play in metastasis.
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Fig 9. TrkB inhibition arrests the progression of the cell cycle in IMR-32 cells.

Table 1. The reduction of cycling cells is shown to be dose dependent on AZ23

- 27 -

30

% Sub G0

25
20
15
10
5
0
0

1

3
AZ23 ( M)

5

7
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TrkB promotes anoikis resistance
Recent studies suggest that TrkB could play a role in the suppression of anoikis,
which is the self-induced death of the cell (apoptosis) that is caused by the loss of cellmatrix interactions. In 2004, the Peeper lab conducted a genome wide screen and identified
TrkB as a potent and specific suppressor of caspase-associated anoikis of non-malignant
epithelial cells (55). Since TrkB is an important signaling target in neuroblastoma, this
suggests that the aggressive nature and high metastatic potential of the disease could be
attributed to the increased TrkB activation seen in more severe stages of the disease. Other
human malignancies with also a natural over-expression of TrkB, such as prostate (63) and
ovarian cancer (64) have tried to relate this phenomenon to their model. However, little
research has been done to apply this finding to neuroblastoma.
Our previous results indicate that SMS-KCN cells have an abundant level of TrkB
protein and mRNA shown by western and qRT-PCR, so we wanted to test whether their
activation would induce anoikis resistance. SMS-KCN cells were grown in either an
attached environment to simulate primary tumor growth or detached environment in plates
coated with POLY-HEMA to prevent adhesion. As demonstrated previously, BDNF
increases proliferation of neuroblastoma cells when in an attached environment. Since
SMS-KCN cells have an autocrine BDNF loop that is constantly activating TrkB, these cells
were expected to have a basal level of resistance to anoikis. The addition of exogenous
BDNF should further promote this phenotype. Using an Alamar blue proliferation assay, we
first reproduced our results showing 20ng/mL of BDNF promoting the proliferation of
attached SMS-KCN cells as an internal control. Suspension SMS-KCN cells in POLYHEMA coated plates showed a 20% decrease in proliferation due to an anoikis effect.
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However, when the cells in suspension were stimulated with 20ng/mL of BDNF, the
population of cells lost due to anoikis were rescued, shown by a 20% increase in viability
that is similar to the attached control (Fig. 11). The results suggest a full recovery that
parallels the baseline of attached SMS-KCN cells, thus correlating with the previous studies
suggesting that TrkB could play a role in neuroblastoma anoikis resistance.
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Fig 11. TrkB activation promotes anoikis resistance shown by an Alamar blue proliferation
assay

In order to further assess that anoikis resistance can regulated by TrkB expression in
neuroblastoma, a time course assay was studied to analyze how long after BDNF induction
did it take for SMS-KCN cells to provide the maximal anoikis resistance effect. The SY5Y
cell line, which expresses a minimal level of TrkB mRNA and protein previously seen in
Fig. 3, was used as a negative control for the experiment. Cultured SMS-KCN and SY5Y
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cells were grown in a POLY-HEMA coated 96-well plate and treated on day 0 with
20ng/mL of BDNF. BDNF stimulated samples were controlled for by a non-treated
condition at each time point. The results showed a maximal effect in SMS-KCN cells at 24
hours of BDNF stimulation, inducing a 30% rescue rate that had a sustainable signal for up
to 104 hours (Fig. 12). However in SY5Y cells, BDNF stimulation didn’t produce a similar
rescue effect, however were able to show a proliferative response in an adherent
environment. A possible reason to explain our results for SY5Y cells could be that
proliferation in suspension may require a higher level of TrkB stimulation in order to
compensate for the apoptosis due to anoikis. The high expression level of TrkB in SMSKCN cells could counteract the effects of anoikis by its robust proliferative response. These
results together suggest that TrkB activation is important in anoikis resistance, and that the
effect can sustain long after the initial BDNF stimulation.
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Fig 12. Maximal anoikis resistance was seen at 24 hours upon 20ng/mL of BDNF
stimulation in a) SMS-KCN cells compared to the b) negative control cell line SY5Y.

Summary
Several studies have shown that TrkB plays an important role in anoikis resistance,
however this is the first report to demonstrate this phenotype in neuroblastoma cells. Due to
the high expression of TrkB receptors in aggressive stages of the disease, TrkB mediated
anoikis resistance could explain the robust metastatic behavior commonly associated with
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those patients. More work however is needed in order to further elucidate the mechanism
involved in order to better identify additional targets that regulate the resistance.

TrkB mediated cell signaling
We then began to evaluate downstream signaling pathways of TrkB in SMS-KCN
cells to find a potential mechanism of BDNF/TrkB mediated proliferation in neuroblastoma
cells. Trk receptors resemble other receptor tyrosine kinases by dimerizing in response to
ligand stimulation. The active tyrosine kinase phosphorylates specific intracellular tyrosine
residues which serve as attachment sites for Shc and PLC. Once bound to the active
receptor they become phosphorylated by the Trk tyrosine kinase. PLC catalyzes the
breakdown of lipids to (DAG) diacylglycerol and (IP3) inositol 1,4,5 tri-phosphate. IP3 in
turn promotes the release of calcium from intracellular stores while DAG stimulates PKC
activation to modulate cell adhesion and migration. Activation of the SH2 domain of SHC
activates either the Ras/MAPK or PI3K/AKT pathway, which have been shown to lead to
phenotypes such as neuronal development and cell survival respectively (21).
We started by looking at the PI3K/AKT pathway, stimulating SMS-KCN cells with
increasing doses of exogenous BDNF up to 20ng/mL for 10 minutes (Fig. 13). Based on our
previous Alamar blue data in Fig 5, this range of doses were shown to stimulate TrkB
effectively. Initially, we wanted to confirm that activated phospho-TrkB (pTrkB) was
BDNF dose dependent, then whether pPI3K (Tyr199), pAKT (Ser473), and pBAD (Ser112)
followed the trend. Our results confirm previous data shown by Thiele’s lab that the
PI3K/AKT/BAD axis regulates survival in our neuroblastoma model system (19).
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Fig 13. BDNF stimulation activates the PI3K/AKT pathway in a dose dependent manner in
SMS-KCN cells

AKT has been identified as the critical starting point of many important pathways
involved in proliferation, apoptosis, differentiation, and metabolism. In many cancers such
as acute myloid leukemia, one critical target of AKT signaling is the mammalian target of
rapamycin (mTOR), which has been implicated as important for the proliferation, growth,
and survival of the cells (65). This novel axis however has not been fully researched in
neuroblastoma.
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Fig. 14. Model of tyrosine kinase activated PI3K/AKT/mTOR axis

mTOR is a serine/threonine protein kinase that belongs to the phosphatidylinositol
3-kinase-related kinase protein family, implicated as the nutrient sensor responsible for
growth and proliferation. Upon TrkB activation, AKT becomes phosphorylated. AKT acts
to prevent TSC1 and 2 inhibition of Rheb, which in turn activates mTORC1. However,
another pathway exists where PI3K activated PDK1 can also act directly on p70S6K to
regulate the mTOR phenotype without the help of AKT. (Fig 14) To elucidate the potential
mTOR mechanism, we assayed p-mTOR at Ser2448 and its known downstream targets
p70S6k at Thr389 and Thr421/Ser424 and RPS6 at Thr235 (Fig. 15).
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Fig 15. BDNF induces a dose response mediated activation of the mTOR pathway

The known downstream targets of mTOR, p70S6K and S6, followed a BDNF dose
dependent trend, shown to become active by 2.5ng/mL of BDNF. mTOR wasn’t shown to
be phosphorylated until 20ng/mL of BDNF stimulation, suggesting that PDK1 may play a
direct role in regulating the mTOR proliferative phenotype. To test whether the TrkB
mechanism signaled to mTOR by means of PI3K/PDK1 or PI3K/AKT pathways, we used
the PI3K inhibitor LY294002 and the AKT inhibitor Triciribine. LY294002 acts as a
competitive inhibitor for ATP binding site of the enzyme, shown previously to inhibit the
proliferation of choroidal melanoma cells (66). Triciribine is a tricyclic nucleoside that has
been shown to selectively inhibit the phosphorylation and activation of AKT, and not its
upstream activators PI3K or PDK1 nor any other parallel pathways such as ERK1/2,
STAT3, PKC, or JNK. Triciribine has been previously shown to effectively inhibit the
growth of AKT-overexpressing melanoma cell lines in vitro and in vivo (67). Both of these
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inhibitors would be used to test whether BDNF mediated proliferation could still take place
when either the function of AKT or PI3K would be inhibited. The experiment would show
that if inhibiting the function of AKT doesn’t prevent BDNF mediated proliferation, but
inhibiting PI3K does, it would further suggest that the PI3K/PDK1 pathway might signal
directly to p70S6K instead of going through AKT. A range of relevant concentrations (0 –
10 M) of each inhibitor was used in an Alamar blue proliferation assay with SMS-KCN
cells +/- 10ng/mL of BDNF. The BDNF concentration was chosen based from my previous
western blot data to provide the most profound stimulation of pTrkB, thus giving the
inhibitors the best chance to decrease the proliferation induced by activated TrkB. SMSKCN cells were plated over night and a concentration range of each inhibitor was used (0 –
10 M) +/- 10ng/mL of BDNF. After 72 hours of incubation, our results showed that
10ng/mL of BDNF was still able to promote proliferation with both inhibitors, seen by the
sustained increase of proliferation over the non BDNF treated control (Fig. 16a,b). To
verify whether 10 M of the AKT inhibitor Triciribine was actually preventing the
phosphorylation and activation of AKT, we analyzed its efficacy by western blot (Fig. 16c).
The decrease in pAKT signal from BDNF alone to the Triciribine/BDNF combination
showed that the inhibitor worked efficiently. In addition, the western blot also showed no
cross reactivity with the close by signaling pathway MAPK, shown as having no significant
change in protein expression between BDNF alone and Triciribine/BDNF combination.
These results suggest that neither AKT nor PI3K are the main factors important for BDNF
mediated proliferation. Furthermore, this also suggests that the mTOR pathway through
either PDK1 or AKT direct stimulation does not play an important role in the proliferation
of SMS-KCN cells either.
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Fig 16. TrkB mediated proliferation is not regulated through a) AKT or b) PI3K signaling. c)
The efficiency of the AKT inhibitor, Triciribine, was measure by western blot

Another pathway that has been extensively explored downstream of TrkB is the
MAPK pathway, which has also been shown to be important to the development of neurons.
We first wanted to test whether targets of the MAPK pathway could be stimulated using
exogenous BDNF.
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Fig 17. Exogenous BDNF stimulates MAPK pathway in SMS-KCN neuroblastoma cells

By stimulation with 100ng/mL of BDNF for 10 minutes, we showed that we could stimulate
the pathway as seen by the increase in activation of pMEK (Ser217/221) and pMAPK
(Thr202/Tyr204) compared to basal levels using Beta Actin as a loading control (Fig. 17).
From here, we then wanted to see if this could be the major regulator in BDNF mediated
proliferation. However, using the common MEK inhibitor, MEK inhibitor I (0 - 10 M) +/10ng/mL of BDNF over a 3 day incubation period, BDNF-mediated proliferation was not
prevented, shown by an Alamar blue proliferation assay (Fig 18).
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Fig 18. MAPK pathway inhibition through MEK doesn’t prevent BDNF mediated
proliferation

Although PLC has been implicated as important for mainly cell adhesion and
migration of neurons, we wanted to test whether it could play a role in BDNF mediated
proliferation in neuroblastoma (68). Using the PLC inhibitor, U73112, we analyzed BDNF
mediated proliferation using +/- 10ng/mL of BDNF in an Alamar blue proliferation assay.
We found similar results to the AKT, PI3K, and MEK1 inhibitors, namely that BDNFmediated proliferation was not inhibited. This suggests that on its own, PLC is not
important in BDNF mediated proliferation (Fig 19).
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Summary
Our results suggest that after analyzing the common pathways for TrkB mediated
signaling (AKT, MAPK, and PLC ), none of the pathways were individually responsible for
BDNF mediated proliferation. This was seen by the inability of each kinase inhibitor for the
three common proximal signaling pathways to prevent BDNF induced increase of
proliferation (10ng/mL of BDNF), as analyzed by an Alamar blue proliferation assay.
Therefore, we examined other potential single pathways of TrkB that haven’t been fully
elucidated in neuroblastoma, starting with the Src family kinases.
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Chapter 3
Fyn regulates TrkB mediated proliferation
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RATIONALE
The Src family of kinases is a family of non-receptor tyrosine kinases that have been
implicated in various phenotypes that promote carcinogenesis. Interestingly, the Src family
member, Fyn, has been shown to be an important pro-differentiation prognostic marker in
neuroblastoma: up-regulated in lower stages and down-regulated in high stages of the
disease. However, the mechanism to explain this Fyn controlled phenotype is unknown.
Previous research has linked Fyn activation with TrkB in neuronal cells, such as in the
process of enhanced learning and memory during chronic multiple stress (69). However, the
role that Fyn might play in TrkB signaling to induce neuroblastoma proliferation still
remains unknown.
To determine the importance of Fyn to neuroblastoma cells, we acquired lentiviral
GFP constructs for constitutively active Fyn, over-expressed wild type Fyn, and dominant
negative Fyn, generously provided by Dr. Joya Chandra (MD Anderson Cancer Center).
She had previously used these constructs to analyze how oxidative stress promotes the upregulation of Fyn in chronic myelogenous leukemia cells (70). By analyzing a variety of
methods to transfect the Fyn constructs, we ultimately found that from a panel of
neuroblastoma cell lines, transient transfection of NGP cells by the lipid based reagent
produced the highest transfection efficiency. The transfection efficiency was measured by
GFP expression by flow cytometry. SMS-KCN cells would have been the optimal cell line
to continue working with, however the cells were not permissive in accepting the constructs.
However, the transfection efficiency would not be suitable enough to analyze by methods
such as RT-PCR or western blotting. We needed a strategy to look at Fyn expression in the
few cells that were transfected, amidst a large population of non-transfected cells. To
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address this issue, we established an assay called phospho-flow using flow cytometry, which
would analyze markers on a single cell basis. We analyzed the subgroup of cells have been
previously transfected with GFP tagged Fyn constructs by probing with the primary
antibodies for phospho-Src family (Tyr416) and phospho-Fyn (Tyr530). Due to similar
structural motifs of their activation loops, the Src family antibody detects the endogenous
phosphorylation at Tyr416 of all the family members to show an upregulation of enzyme
activity. The phospho-Fyn specific antibody recognizes endogenous levels of Fyn when
phosphorylated at the Tyr530 site. The expression of activated Fyn as well as a general
activation of the Src family members was measured in relation to GFP produced by the
transfected constructs. After the transfection, we waited for 48 hours to achieve maximal
expression, then fixed the cells and permeabilized them using a Cytofix/Cytoperm kit. The
primary antibodies for phospho-SFK and phospho-Fyn were used, followed by a PEconjugated secondary antibody. A secondary antibody only negative control was used for
each sample to give a non-specific binding fluorescence level. We compared the activation
of Fyn and general Src family members by creating a ratio between the mean fluorescence
intensity of PE signal in the GFP+ subpopulation compared to the GFP- population (Fig 20).
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Fig 20. a) Both constitutively active (CA) and over expressed wild type (WT) Fyn constructs
promoted an increase in PE signal for pSrc and pFyn expression, analyzed by flow
cytometry. The mean fluorescence intensity for b) pSrc and c) pFyn was analyzed relative
to a migR1 control.
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Compared to a migR1 GFP expression control, we found that the constitutively
active construct produced ~7 fold higher activation of Src family members and ~2 fold
higher activation of Fyn. Surprisingly, the over-expressed wild type construct produced a
similar result, ~5 fold higher in phospho-Src family and ~1.5 fold higher in phospho-Fyn
expression than compared to migR1 control. This trend shows that when the cell is overexpressed with the wild type Fyn construct, the expression of activated Fyn is nearly as high
as that by the constitutively active construct, suggesting that Fyn becomes readily activated
whenever available.
To test whether Fyn is important to neuroblastoma proliferation, we probed the
transfected cells for PCNA, a well established marker of proliferation. Proliferating cell
nuclear antigen (PCNA) is a member of the DNA sliding clamp family of proteins that assist
in DNA replication. Again using intracellular flow cytometry, we stained cells transfected
with the Fyn constructs using an antibody to PCNA and a secondary antibody conjugated to
PE. We found that both over expressed wild type and constitutively active Fyn inhibited
proliferation as seen by the decrease of PCNA expression; the constitutively active construct
producing a 70% decrease and the wild type a 20% decrease (Fig. 21). This suggests that
high expression of activated Fyn plays an inhibitory role in neuroblastoma proliferation.
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Fig 21. PCNA expression decreases relative to GFP+ expression from constitutively active
(CA) and over expressed wild type (WT) Fyn constructs compared to a migR1 control.

To determine the role of wildtype and constitutively active Fyn on neuroblastoma
proliferation and survival, we began by transfecting NGP cells with the Fyn constructs.
Cells were then collected on days 1 and 4 and analyzed by flow cytometry for GFP
expression. Results were normalized to the transfection efficiency of Day 1 (Fig. 22). We
show that migR1 expression increased from day 1 to day 4, showing the time for maximal
GFP expression following transfection. However, a rapid decrease of GFP expression was
seen in cells with wild type and constitutively active Fyn on day 4, suggesting that the Fyn
transfected cells did not proliferate as quickly compared to the migR1 control. This finding
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correlates with previous studies suggesting that high expression and activity of Fyn causes a
growth inhibitory phenotype in neuroblastoma.
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Fig 22. GFP expression of both Fyn constructs decreases faster over time compared to a
migR1 control

We have shown that Fyn is important to neuroblastoma cell proliferation, however
whether this phenotype has a connection with TrkB is still unknown. Previous research has
shown a potential role for the interaction between Fyn and TrkB as a regulator of
hippocampal NMDA receptor activation as a way to enhance spatial learning (71).
However, the interaction between the two proteins has never been studied in regards to
neuroblastoma proliferation. As an initial test, we used the general Src family kinase
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inhibitor, PP2, to test whether the inhibition of Src family kinases would promote the
proliferation of SMS-KCN cells. Cells were grown in a 96-well plate and treated with +/20ng/mL of BDNF and/or PP2 for 72 hours in an Alamar blue proliferation assay (Fig. 23).
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Fig 23. Inhibition of Src family kinases cooperates with TrkB activation to promote
neuroblastoma proliferation shown by an Alamar blue proliferation assay

As a control test, we show that BDNF (20ng/mL) induced a 20% increased in
proliferation of SMS-KCN cells, seen previously in our past results. With the use of 1nM of
PP2, our results show that the Src family inhibitor increased the proliferation of SMS-KCN
cells to a similar level of BDNF stimulation (~16% increase). To test whether Src family
members played a role in BDNF-induced proliferation, a combination of PP2 to BDNF
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treatment of the cells led to a 30% increase in proliferation compared to BDNF induced cells
with no PP2. This result suggests that the combination of TrkB activation with Src family
inhibition promoted increased proliferation. These trends were confirmed by cell counts;
1nM of PP2 +/- 10ng/mL of BDNF in SMS-KCN cells (Fig. 24). These data suggest that
inhibiting Src family kinases cooperates with TrkB activation as a mechanism to promote
neuroblastoma proliferation.

Fig 24. Inhibition of Src family kinases (1nM) cooperates with TrkB activation to promote
neuroblastoma proliferation shown by cell counts

To determine if Fyn is the member of the Src family kinases responsible for
cooperating with TrkB to induce proliferation, a shRNA to Fyn was used to directly inhibit
activity by silencing its gene expression. NGP cells were transiently transfected with the
Fyn GFP tagged shRNA, an empty GFP tagged vector control (negative), and a GFP tagged
scrambled control using Lipofectamine 2000. Phospho-flow was conducted in order to
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validate that the shRNA could knock down Fyn activation by probing with a p-Fyn (Tyr530)
antibody and a PE conjugated secondary antibody. The mean fluorescent intensity of FynPE expression was taken for GFP+ and GFP- groups for each vector. The background
fluorescence was determined by the secondary only control, and pFyn results were
calculated relative to its expression. We show that for the scrambled and vector (negative)
controls, the mean fluorescent intensity for PE produced nearly the same value between
GFP+ and GFP- cells. However, the Fyn shRNA decreased the expression of p-Fyn by 15%
in GFP+ cells compared to GFP- cells, suggesting this shRNA works properly (Table 2).

mean PE of GFP+

mean PE of GFP-

negative control

28.2

23.3

negative secondary only

44.1

44.6

negative pFyn

176

176

27.6

23.3

34.2

32.3

scrambled pFyn

225

224

shRNA control

28.2

23.9

38.6

39.7

179

206

scrambled control
scrambled secondary only

shRNA secondary only
shRNA pFyn

15% decrease in
pFyn expression

Table 2. Validation of Fyn shRNA by phospho-flow shown by the 15% decrease of the
mean fluorescence intensity of pFyn in the shRNA GFP+ subset of cells compared to the
GFP- cells. This system was controlled for by an empty vector (negative) and scrambled
shRNA vector.
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Next we wanted to analyze whether Fyn plays an important role in TrkB mediated
proliferation. NGP cells were transfected with the Fyn shRNA or a scrambled control at a
similarly high efficiency (Fig. 25a), as shown by GFP signal relative to the size of the cells,
dictated as side scatter (SSC). These cells were then directly subjected to an Alamar blue
proliferation assay with a range of BDNF concentrations (0 – 10ng/mL) for 72 hours (Fig
25b). At each BDNF concentration, the Fyn shRNA reading was calculated relative to a
corresponding scrambled control. The results show that by silencing Fyn gene expression
by the shRNA, BDNF mediated TrkB activation further induced the proliferation of the cells
in a dose-dependent manner. This result confirms previous reports that TrkB and Fyn
cooperate together, and also suggests a potential mechanism behind TrkB proliferation in
neuroblastoma. We believe that upon activation of TrkB by BDNF, Fyn becomes recruited
and forms a complex through its SH2 domain to the activated receptor. The BDNF
mediated complex then goes on to promote the proliferation of the cells.
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Fig 25. a) Transfection efficiency between the Fyn shRNA and scrambled shRNA are
similarly high in NGP cells b) Fyn cooperates with TrkB to induce proliferation, shown by a
BDNF dose response effect
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Summary
Previous research has identified several common signaling pathways that may
explain the roles that TrkB receptors play in various systems; from chemo-resistance and
survival to neuronal development. In addition, here we show that the promotion of Fyn
expression and activity promotes the differentiation of neuroblastoma cells. Constitutively
active and wildtype Fyn expression inhibited proliferation of the cells seen by the reduced
expression of PCNA. Conversely, the inhibition of the Src family members by PP2
treatment along with BDNF stimulation enhanced proliferation of neuroblastoma cells. This
effect was found to be a Fyn specific event, shown by a shRNA knockdown of Fyn
expression cooperating with BDNF stimulation to promote proliferation.
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Chapter 4
BDNF mediated cell cycle regulation
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Rationale
Although TrkB activation has been implicated in the proliferation of neuroblastoma
cells, little is known about its effects on cell cycle regulation. We wanted to identify
important downstream cell cycle regulators to further characterize the mechanism behind the
phenotype. To decipher the progression of which specific targets are activated upon TrkB
activation, we conducted a 27 hour time course study of BDNF stimulation in SMS-KCN
cells.

BDNF (20ng/mL)
Time (hours)

0

0.5 1

2

4 10 16 27

pTrkB Y817
Total TrkB
pPI3K Y199
pAKT S473
-Actin
Fig. 26. BDNF simulation maximizes the activation of TrkB and its downstream targets
PI3K and AKT until 4 hours.
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Exogenous BDNF stimulation can be seen by the initial phosphorylation of TrkB.
Protein expression of pTrkB was shown to be increased over baseline until 4 hours where its
expression decreases to under baseline (Fig. 26). We believe that when there is no
exogenous BDNF in the system, there exists a controlled feedback loop between TrkB
activation through its autocrine BDNF loop and receptor turnover rate. This accounts for
the continuous high expression of pTrkB seen in non-stimulated SMS-KCN cell. However,
when exogenous BDNF is added, the increase in TrkB activation disrupts this loop by
activating more TrkB receptors at once. This in turn causes a greater number of receptors to
be recycled, limiting the activation over a longer period of time. Potentially this could be
studied by fluorescently tagging TrkB receptors and stably transfecting them into a cell line
that has a minimal level of TrkB, such as the SY5Y cell line. The fluorescent tag can then
be tracked after the initial BDNF stimulation, comparing cell surface expression to
intracellular expression. In addition to the TrkB activation length, we also expected to see a
similar trend with PI3K (Y199) and AKT (Ser473), since they are just downstream of TrkB.
The results showed that their activation was also maximized until 4 hours, but their
activation persisted significantly above the 0 time point baseline. This suggests that even
after the initial BDNF stimulation of TrkB, the signal persists through various pathways that
can lead to beneficial phenotypes such as cell survival and chemoresistance.
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Fig 27. BDNF simulation initially activates Rb and its upstream target CDK4/cyclin D
complex during the cell cycle process

After confirming BDNF induction promotes the activation of TrkB targets as an
internal control, we wanted to establish the effect on the retinoblastoma tumor suppressor
protein, (Rb). Rb has been elucidated as an important regulator of neuronal differentiation
by the decrease the phosphorylation level of Rb as well as cyclin-dependent kinase (CDK)
activity (72). Conversely, the proliferation of cells would promote the opposite trend:
increasing the phosphorylation of Rb and formation of CDK complexes. Since BDNF has
shown to promote proliferation of neuroblastoma cells, we wanted to analyze the status of
these cell cycle regulators. Upon phosphorylation, Rb becomes inactive and subsequently
detaches from E2F to promote a G1/S-phase gene expression that dictates growth and
division of the cell. A number of proliferative signals such as PCNA are then activated by
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E2F-mediated transcription. Our results show that Rb (Ser608) responds to BDNF induction
quickly by 0.5 hours and persists throughout the time course experiment, confirming that Rb
is important to BDNF-mediated proliferation in neuroblastoma cells (Fig. 27). A potential
pathway that regulates Rb is the cyclin dependent kinase 4 (CDK4)/ cyclin D pathway,
which affects the cell’s entry into S-phase of the cell cycle. Our results show that the early
increase in expression of CDK4 and cyclin D correlate with Rb activation, suggesting a
potential mechanism for early entry into the cell cycle.

BDNF (20ng/mL)
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cdc25a
pCDK2 T160
Cyclin E
-Actin
Fig 28. BDNF stimulation upregulates cdc25a and cyclin E and activates CDK2 after 4
hours.

Another direct regulator of Rb is the CDK2/cyclin E complex, shown to be important
for the G1 to S transition of the cell cycle. During S-phase, the active CDK2/cyclin E
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complex continues the phosphorylation of Rb once the CDK4/cylin D complex has
dissociated, in order to further promote proliferation. cdc25A is known to promote the
complex formation of CDK2/cyclin E by removing the inhibitory phosphates on CDK2
(Thr14 and Tyr15), which then leads to the phosphorylation at Thr160 by a cyclin activated
kinase (CAK). Our results show that the activation of cdc25A correlates with the expression
level of cyclin E by an increase only after 4 hours (Fig. 28). Even though CDK2 is activated
(Thr160) early in the cell cycle when compared to basal levels, complex formation most
likely doesn’t take place till after 4 hours. This is suggested by the increase of pCDK2
expression at 10 hours and onward, which mirrors cyclin E expression at that point.
Summary
These results suggest that BDNF promotes the proliferation of neuroblastoma cells
through the activation of both the CDK4/cyclin D and CDK2/cyclin E complexes.
However, these complexes are shown to be important for the dissociation of Rb from E2F to
promote proliferation through BDNF induction. CDK4/cyclin D complex prepares the cell
to enter S phase by partially inactivating pRb in early G1 phase. Then the CDK2/cyclin E
complex promotes the entry into S phase by completely inhibiting the binding of pRb to
E2F, allowing for uninhibited E2F mediated proliferation (Fig. 29). Cell cycle deregulation
plays a major role in the aggressiveness of a tumor, due to unrestrained proliferation. A
variety of reasons my cause this such as a mutation in Rb that keeps it inactivated or an
upregulation of Rb phosphorylation due to ligand stimulation. In the case for SMS-KCN
cells, inhibiting the phosphorylation of Rb would serve to inhibit the growth and
proliferation of the cells, since no known mutations of Rb exist for neuroblastoma. The
CDK4/6 small molecule inhibitor, PD-0332991, has shown to induce a G1 arrest in primary
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bone marrow myeloma cells. The inhibitor blocks CDK4, which prepares the cell to
transition to S phase, as well as CDK6, which is important for the progression into S phase
(73). We believe that if this inhibitor were used in neuroblastoma cells, proliferation of the
cells could be inhibited by essentially preventing BDNF mediated phosphorylation of Rb.

1. CDK4/cyclinD complex
prepares cell to go into S phase

2. cdc25A releases inhibitory phosphates from
CDK2 to allow CDK2/cyclin E complex
formation and promotion of cell to S phase
cdc25A

P

CDK4
cyclin D

CDK2
cyclin E

checkpoint

G1 phase

S phase
proliferation

Rb

Fig 29. Summary of results for BDNF mediated proliferation through cell cycle regulation in
neuroblastoma
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Chapter 5
Discussion
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Characterizing TrkB mediated proliferation in neuroblastoma
We characterize the role TrkB plays in neuroblastoma in a non-over expressed setting,
which has been difficult to do in the past. We used the SMS-KCN cell line as a model for
neuroblastoma. The high expression of TrkB and high sensitivity to BDNF allowed low
BDNF concentrations to be used, thus minimizing non-specific binding. Previous findings
confirmed by our results showed a minimal expression of the low affinity neurotrophic
receptor, p75NTR (74). In addition, it was also previously shown that TrkA doesn’t signal
downstream in SMS-KCN cells, suggesting that BDNF stimulation would provide a clear,
distinct signaling pathway (17). These characteristics combined make this cell line an
excellent candidate to study TrkB signaling.
All of the neuroblastoma cells lines tested responded to BDNF stimulation with a
mean proliferative increase of 43%, suggesting that TrkB plays a critical role in
proliferation. However, SMS-KCN cells were shown to be more sensitive to BDNF
stimulation as well as Trk inhibition by AZ23, suggesting a greater dependence on TrkB
than other cells.
IMR32 cells were used in order to show that TrkB plays an important role in
proliferation as analyzed by its effect on cell cycle regulation. A propidium iodide based
flow assay demonstrated that inhibition of TrkB function promoted a G2/M arrest in the
cells as well as an increase in the sub-G0 population. This result further suggests the
importance of TrkB signaling at baseline by the presence of endogenous BDNF.
We then studied the role that TrkB played in suspension cells. A recent study
identified TrkB expression as a direct suppressor of anoikis mediated apoptosis in nonmalignant epithelial cells (25, 55). Using the high expression TrkB cell line, SMS-KCN, we
tested to see whether this effect could be seen in neuroblastoma. Since an Alamar blue
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proliferation assay measures the amount of live cells within a well, we used this technique to
analyze the viability of SMS-KCN cells after 72 hours in a POLY-HEMA coated plate,
where the cells could not attach to the bottom compared to cells that could. In addition, we
treated unattached SMS-KCN cells with 20ng/mL of BDNF to see if we could promote
anoikis resistance. Based on our results, we saw that BDNF increased the proliferation of
the cells in an attached setting, as seen in our previous results. For the unattached SMSKCN cells, we saw a full rescue effect due to BDNF induction compared to the attached
control. In addition, we ran a time course study to analyze the maximal effect of BDNF
mediated anoikis resistance in SMS-KCN cells compared to the low TrkB expression cell
line, SY5Y. The results showed a maximal rescue effect of SMS-KCN cells at 24 hours by
BDNF stimulation. These results together suggest that TrkB activation plays a critical role
in promoting anoikis resistance, adding to the metastatic potential of the disease.

TrkB mediated cell signaling
Several signaling pathways have been identified that are important to TrkB function.
The main pathway that has been shown to control chemo-resistance and cell survival in
neuroblastoma is the PI3K/AKT axis (75). However, few targets have been identified
downstream of AKT that may be responsible for the aggressive phenotype associated with
high levels of TrkB in neuroblastoma. Previous research has linked the mTOR pathway as a
potential downstream target of TrkB in leukemias (76), but this axis has not been thoroughly
looked at in neuroblastoma. Our results correlate with previous findings that BDNF induces
a dose-dependent activation along AKT axis. In addition, the downstream targets of mTOR,
p70S6K and the ribosomal protein S6, were shown to be BDNF dose-dependent; stimulated

- 64 -

with as little as 2.5ng/mL of BDNF. This result suggests a potential link between AKT and
mTOR pathways due to TrkB activation. Since mTOR is seen to be regulated by many
different pathways, these results point to the fact that mTOR stimulation is most likely not a
direct cause of TrkB activation, but is activated by downstream TrkB targets instead.
Interestingly we found that the mTOR targets could be stimulated by PI3K/PDK1 directly,
suggesting an AKT/mTOR bypass pathway. To clarify the mechanism, we used potent
AKT and PI3K kinase inhibitors to test whether BDNF mediated proliferation could be
repressed. However the results showed that neither of these inhibitors had any significant
effect in preventing BDNF induced proliferation, suggesting that the PI3K/mTOR or AKT
pathways were not critical for BDNF/TrkB induced proliferation. Additionally, the other
two major pathways extensively studied in neuroblastoma, MAPK and PLC did not have a
significant effect on BDNF mediated proliferation when inhibited pharmacologically. A
possible explanation for our results is that these common parallel pathways could be
redundant in controlling similar signals that would lead to BDNF mediated proliferation.
Thus these pathways would need to be inhibited in combination in order to see the decrease
in cell proliferation.

Fyn regulates TrkB mediated proliferation
We explored alternate pathways that may serve as the important regulator of TrkB
mediated proliferation. Although Src family kinases have not been extensively researched
in neuroblastoma, they have been shown to play an important role in the carcinogenesis of
many other different cancers. Interestingly, the Src family kinase member, Fyn, has been
implicated as a pro-differentiation marker in neuroblastoma. The Eilers lab showed that Fyn
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expression and activity levels could be used to dictate the severity of the disease (44),
however a signaling mechanism was never associated with the finding. We wanted to test
whether Fyn could be a critical factor in BDNF mediated proliferation. Previous reports
suggest that Fyn and TrkB interact with to each other upon activation in hippocampal cells
to promote spatial memory formation (50, 69), but this interaction has never been
characterized in neuroblastoma cells.
We first reproduce previous results found by Eilers that high Fyn expression and
activation elicited a differentiation phenotype in neuroblastoma. The activity for the Fyn
vectors were acquired (constitutively active and over-expressed wildtype Fyn) were
confirmed by flow cytometry, probing for pFyn and pSrc expression. Our results showed
that the constitutively active and over-expressed wild type constructs increase both pFyn and
pSrc expression, and also lowered PCNA expression (proliferative marker). This result
correlates with the idea that high expression of Fyn promotes the differentiation of the cells,
which in turn decreases their proliferation. In addition, the importance of high expression of
activated or wild type Fyn was analyzed by measuring the loss of GFP over time. The idea
was to see whether the Fyn constructs augmented the survival/ proliferation phenotype that
would be “beneficial” to the cells. If they hindered the cells from being aggressive through
proliferation and survival, then they would be selected against. Transfected cells would
become differentiated, not divide as quickly, and eventually be eliminated out of the
population, reducing the rate at which the GFP tag can be passed down through dividing
cells. Our results show that cells with a high expression and activation of Fyn were selected
against compared to cells transfected with a migR1 control, which proliferated like normal.
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This further suggests that Fyn is an important regulator of differentiation in neuroblastoma
cells.
However, inhibiting Fyn expression and activation should promote cells to elicit a
greater proliferative response. Using a general Src family kinase inhibitor, PP2, to treat
SMS-KCN cells in a proliferation assay, our results show an increase in proliferation
compared to a non-treated baseline upon 1nM treatment. Since a number of Src family
members are being inhibited simultaneously, this result could produce a mixed effect by
promoting both proliferation and differentiation. Interestingly, the addition of BDNF
induced a greater proliferative effect, even above BDNF induction alone, hinting at a
possible control mechanism by TrkB. Furthermore, this trend was confirmed by cell counts
in addition to the Alamar blue proliferation assay.
To show that this is truly a Fyn specific event, we obtained shRNA constructs for Fyn.
By phospho-flow probing for pFyn, we show that the shRNA does repress its activity,
identified by the decrease in the median fluorescent intensity of PE signal in GFP+ cells
compared to GFP- cells. NGP cells were then transiently transfected with the shRNA DNA
plasmids and treated with varying doses of BDNF (0, 1, 10ng/mL). When no BDNF was
added, no significant change was seen between the scrambled control cells and the shRNA
to Fyn cells. However, once 1ng/mL of BDNF was added to the system, the Fyn shRNA
cells had a 15% increase over the scrambled control with the same BDNF induction.
Furthermore, when 10ng/mL of BDNF was added, a greater proliferative effect was seen; a
35% increase over the scrambled control with the same BDNF induction. The results show
that the repression of Fyn activity promotes proliferation in NGP cells in a BDNF dose-
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dependent mechanism. These results suggest that Fyn specifically plays a critical role in
TrkB mediated proliferation.

TrkB mediated cell cycle regulation
Our results confirm those seen previously suggesting that BDNF activated TrkB
plays an important role in the proliferation of neuroblastoma cells. However, little research
has been done to characterize the downstream cell cycle regulators that promote this
phenotype. A time course western blot experiment using 20ng/mL of BDNF stimulation
was conducted to elucidate the order of activated proteins targets within the pathway. We
first reproduced our results showing TrkB, PI3K, and AKT activation using BDNF
stimulation as a control. In addition, the blots provided insight as to how quickly the
activation of these upstream targets took place, showing an increase of expression lasting up
to 4 hours. Similarly, retinoblastoma protein tumor suppressor (Rb) became inactivated
early on by phosphorylation, which is an important regulator in proliferation. Our results
show that a known regulator of Rb, CDK4/cyclin D complex, has an expression that is also
up-regulated early on as well, suggesting a potential mechanism that prepares cells to enter S
phase shortly following BDNF induction. The CDK2/cyclin E complex also becomes
increasingly expressed after 4 hours, which could play a role in promoting the cells that have
already been prepared by the CDK4/cyclin D complex to go into S phase.
A common regulator of CDK2/cyclin E complex formation is cdc25a, which is
known to degrade in response to DNA damage, resulting in cell cycle arrest. In addition to
being a cell cycle regulator, it has also been implicated as an oncogene. The increased
expression of cdc25A correlating with CDK2/cyclin E suggests continual promotion of S

- 68 -

phase entry, shown to occur long after TrkB has been activated. This trend proposes that if
the micro-environment contains even a minimal concentration of BDNF, this could promote
a proliferation signal that could sustain long after the initial signal, adding to the aggressive
nature of the disease.
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Conclusions
Trk receptors have been implicated in various systems, playing both positive and
negative roles on oncogenesis depending on the tumor type. Although TrkB expression and
activation in neuroblastoma have been shown to promote cancerous phenotypes and
contribute to a poor prognosis of the disease, their signaling pathways have remained a
mystery. Elucidating these mechanisms would better identify relevant targets that may be
used in the treatment of the disease.
BDNF mediated signaling through TrkB has shown to be a critical factor in the
regulation of proliferation in neuroblastoma cells, both in attached and suspension
environments. Key cell cycle proliferative regulators such as Rb were shown to be directly
regulated by BDNF. The interaction between TrkB and Fyn was found to be a critical link
that helps explain the mechanism behind BDNF mediated proliferation.

We demonstrate that:
1. BDNF dose dependently induces proliferation in a panel of neuroblastoma cell lines
This was demonstrated inducing a panel of cell lines with a range of BDNF
concentrations to produce a proliferative response.
2. TrkB expression level was correlated with sensitivity to BDNF
This was demonstrated by correlating the much higher TrkB protein/mRNA levels of
SMS-KCN cells with the ability to respond to picogram concentrations of BDNF to
induce a proliferative response against a panel of other cell lines.
3. Although TrkB induces the activity of PI3K/AKT, MAPK, and PLC , none of these
pathways individually are critical for BDNF mediated proliferation
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Pathways were shown to be activated through a BDNF dose response as seen by
protein expression. Specific inhibitors of each pathway did not prevent the
proliferative increase that BDNF induces in SMS-KCN cells.
4. Activation of TrkB may play an important role in promoting anoikis resistance
This was demonstrated by the full rescue of anoikis mediated apoptotic SMS-KCN
cells with a maximal effect at 24 hours.
5. Expression of constitutively active and over expressed wild type Fyn decreases
proliferation
This was demonstrated by a decrease of PCNA expression of cells when transfected
with the constitutively active or over-expressed wild type Fyn constructs. GFP
expression over time of transfected cells showed that these constructs were not
beneficial to the health of the cells compared to a migR1 control.
6. The inhibition of Fyn cooperates with TrkB to increase proliferation of
neuroblastoma cells
This was demonstrated by the cooperation between knocking out Fyn function by
shRNA while stimulating with BDNF to produce a more robust proliferative effect in
SMS-KCN cells.
7. BDNF induces the periodic activation and expression of CDK4/cyclin D and
CDK2/cyclin E complexes, associated with increase in pRb.
This was demonstrated by the increase of protein expression of cell cycle regulators
at specific times to promote the progression into S-phase by Rb activation.
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Future Directions
To further elucidate the mechanism that regulated BDNF mediated proliferation in
neuroblastoma, our next step would be to see how cell cycle regulators would be affected
relative to the activity and expression level of Fyn. We predict that over expressed wild type
and constitutively active Fyn would promote a G1 arrest, most likely affecting the
phosphorylation of Rb by a decrease in CDK4/cyclinD and/or CDK2/cyclin E complex
formation. Conversely, the inhibition of Fyn would promote the dissociation of Rb from
E2F, thus leading to an increase in proliferation. Due to previous studies suggesting the
interaction between TrkB and Fyn (52-54, 71), we believe the addition of exogenous BDNF
could activate Fyn to promote a differentiation phenotype in neuroblastoma cells. The use
of common differentiation markers such as synapsin and MAP2 would be compared to
retinoic acid induced differentiation, which has been extensively studied in neuroblastoma
(77). TrkB could play a dual role in balancing differentiation as well as cell survival and
proliferation by the activation of multiple pathways. Logically, this makes sense because
TrkB shares many proximal pathways with the pro-differentiation signaling of TrkA. The
crossover between the two signaling pathways is possible, which may explain why the roles
of TrkA and TrkB in some systems such as melanoma (78) and prostate cancer (79) are
reversed; TrkB is pro-differentiation and TrkA is pro-proliferation.

- 72 -

Chapter 8
Materials and Methods

- 73 -

Neuroblastoma cell culture
Neuroblastoma cells were grown at 37°C in 5% carbon dioxide. RPMI-1640
(Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (USB),
2mmol/L L-glutamine, 1mmol/L nonessential amino acids, 1 mmol/L penicillinstreptomycin, 1mM sodium pyruvate, and 10mM hepes (Sigma Chemical Company).

Therapeutic Agents
BDNF (Peprotech) stock solutions of 100mg/L were prepared in water and stored at
20°C. AZ23 was provided by AstraZeneca (Macclesfield). Stock solutions were generated
using dimethyl sulfoxide (Sigma Chemical Company) and stored at 20°C. Before use, a
10mM stock solution was made using phosphate-buffered saline (PBS) and 30% acetic acid.

DNA Vector Constructs
The constitutively active and over-expressed wild type Fyn constructs used in this
study were generously provided by Dr. Chandra (MD Anderson). shRNA for Fyn was used
in knockdown experiments (Origene).

Alamar Blue proliferation assays
Neuroblastoma cells were plated in a 96-well plate (~15,000/well) in triplicate and
allowed to adhere overnight. BDNF/drug combinations were added on day 0 and incubated
for 72 hours at 37°C. Then 10 L of Alamar blue dye (Invitrogen) was added to each well
on day 3 were incubated at 37°C for at least 2 hours. Plates were analyzed by a Spectramax
Gemini EM spectrophotometer (Molecular Devices) at 544nm and 590nm. Change in
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proliferation was calculated by dividing the relative fluorescence value of the treated group
from the untreated group.

Taqman Quantitative Reverse Transcriptase-Polymerase Chain Reaction
Neuroblastoma cells were grown to near-confluence on 10-cm tissue culture plates.
Cells were harvested and RNA was purified using Qiagen RNeasy Mini-kits following
(Qiagen) and quantified using a Nanodrop 1000 spectrophotometer (Nanodrop). Then
cDNA was synthesized using the Omniscript reverse transcription kit (Qiagen). Taqman
quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) using specific
primers for TrkA, TrkB, TrkC (NTRK1, NTRK2, and NTRK3) and p75NTR (Applied
Biosystems) was performed in triplicate using a BioRad iCycler iQ real-time PCR detection
system. Relative levels of each sample were normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH).

Western Blot
Neuroblastoma cells were plated on 10-cm dishes and grown until approximately
70% confluent. The night before treatment, cells were washed with PBS and serum free
media was added. For BDNF only experiments, 20 or 100ng/mL of BDNF was added to
media 10 minutes before lysing. For AZ23/BDNF experiments, cells were treated with
25nM or 50nM of AZ23 for 50 minutes, followed by 0 – 100ng/mL of BDNF for an
additional 10 minutes. For the BDNF/Triciribine experiment, cells were treated with 10mM
of Triciribine for 50 minutes, followed by 10ng/mL of BDNF for an additional 10 minutes.
The media was then aspirated and a combination of PhosphoSafe Extraction Reagent
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(Novagen) with 10% protease inhibitor was used to lyse cells directly. Cells were rocked in
4 degree cold room for 30 minutes. Protein concentrations were determined using BCA
assay kit (Pierce). Protein lysate (50 g) was analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 0.22 M polyvinylidene
fluoride (PVDF) membrane. Membranes were blocked with 5% milk in TBST and
incubated with the indicated primary antibodies, diluted according to manufacturer’s
recommendations. Phosphorylated TrkB – LifeSpan Biosciences LS-C50093
Total TrkB – R&D Systems – AF397
Phosphorylated PI3K – Cell Signaling #4228S
Phosphorylated AKT – Cell Signaling #9271S
Phosphorylated BAD – Cell Signaling #9291S
Phosphorylated mTOR – Cell Signaling #2971
Phosphorylated p70S6K – Cell Signaling #9205
Phosphorylated protein S6 – Cell Signaling #2211S
Phosphorylated MEK ½ - Cell Signaling #9102
Total MEK ½ - Cell Signaling #9126
Phosphorylated ERK ½ (MAPK) - Cell Signaling #9154S
Phosphorylated Rb - Cell Signaling #2181
CDK4 - Cell Signaling #2906
Cyclin D - Cell Signaling #2922
Cdc25A – Cell Signaling #3652
Phosphorylated CDK2 – Cell Signaling #2561S
Cyclin E – Santa Cruz 247
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Beta Actin – Sigma A5441
Probes were detected with appropriate horseradish peroxidase (HRP)-conjugated secondary
antibodies (GE Healthcare) and developed with the ECL Western Blotting Analysis System
(Amersham) and a Kodak film developer (Eastman Kodak).

Flow Cytometry – Cell surface staining
SMS-KCN and SY5Y cells were grown in 6-well dishes until about 70% confluency.
The cells were then extracted, washed with PBS, and appropriately stained for. For each
cell line, there was an unstained control, PE secondary only control, and total extracellular
TrkB primary antibody (R&D systems, AF397) with PE secondary antibody. A relative
TrkB cell surface expression was found by dividing the mean fluorescent PE intensities for
the TrkB stained samples from the PE secondary stained alone.

Flow Cytometry – Cell cycle
IMR-32 cells were treated with varying doses of AZ23 (1 – 7mM) for 1 hour in a 6well plate before being washed in PBS. Cells were then fixed in 70% ethanol overnight at 20°C. Samples were washed with PBS and then stained with 0.1 mg/ml PI in 0.6% Triton-X
in PBS for at least 30 minutes in the dark. Cell cycle was then analyzed by FACSCalibur
(BD Biosciences).
Flow Cytometry – GFP
A panel of neuroblastoma cells were transfected with a constitutively active or wildtype construct using either Lipofectamine 2000 (Invitrogen) or Fugene 6 (Roche)
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transfection kits. Relative GFP expression was measured compared to a migR1 control by
FACSCalibur (BD Biosciences).

Flow Cytometry – Intracellular Staining
NGP cells were transfected with a constitutively active or wild-type Fyn construct
using Lipofectamine 2000 (Invitrogen). Maximal GFP expression was achieved after 48
hours of incubation at 37°C. Cells were then permeabilized and fixed using
Cytofix/Cytoperm (BD Biosciences). In order to maintain permeabilization of the cells
throughout the staining process, a mixture of 0.1% saponin (Sigma) and 1% FBS in PBS
was used for washes and antibody diluents. Phosphorylated Src family kinases antibody,
pSrc (Cell Signaling #2101S), phosphorylated Fyn (Novus Biologicals, NB100-92535), or
PCNA (Cell Signaling #2586) were used in conjunction with a PE-conjugated secondary
antibody according to the manufacturer’s dilution recommendations. Relative mean
fluorescence intensity for GFP vs. PE expression for each primary antibody was compared
to a migR1 control, as analyzed by FACSCalibur (BD Biosciences).

Alamar blue proliferation assay – shRNA to Fyn
NGP cells were transfected with the Fyn shRNA or a scrambled control (Origene)
using Lipofectamine 2000 in a 6-well plate. A portion of the cells were used to analyze GFP
expression by FACSCalibur. The other portion of cells (15,000 cells/well) were plated on a
96-well plate in triplicate and stimulated with a range of BDNF concentrations (0 –
10ng/mL) for 72 hours. Then 10 L of Alamar blue dye was added and the plate was read in
the same way as previously described.
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Alamar blue proliferation assay – anoikis resistance
SMS-KCN cells were seeded into a 96-well plate (15,000 cells/well) in triplicate
with wells coated with poly-2-hydroxyethyl methacrylate (POLY-HEMA) to prevent the
attachment of cells to the bottom of the well or a normal bottom that allows attachment.
Cells were treated +/- BDNF stimulation (20ng/mL) for 72 hours. Then 10 L of Alamar
blue dye was added and the plate was read in the same way as previously described.

Alamar blue proliferation assay – anoikis resistance time course
SMS-KCN and SY5Y cells were seeded into a 96-well plate (15,000 cells/well) in
triplicate and treated with 20ng/mL of BDNF from 18-104 hours. 10 L of Alamar blue dye
was added and the plate was read in the same way as previously described.
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